Document Detail


Time-course of health status in patients with rheumatoid arthritis during the first year of treatment with infliximab.
MedLine Citation:
PMID:  19944558     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: A longitudinal study was performed to examine changes in health status in comparison with rheumatoid arthritis (RA) inflammation in patients with RA during the first 54 weeks of infliximab (IFX) treatment. METHODS: Health status in active RA patients (n=13) was assessed monthly using the Arthritis Impact Measurement Scale 2 (AIMS2) and the VAS-GH during the first year of IFX treatment. Simultaneously, RA activity was assessed using inflammation markers, MMP-3 and the Disease Activity Score in 28 joints (DAS-28) based on CRP [DAS-28(CRP)] and ESR[DAS-28(ESR)]. RESULTS: Serum CRP and ESR decreased significantly from 2.14+/-0.52mg/dL and 56.9+/-6.96mm/h, respectively, at baseline to 0.24+/-0.11mg/dL and 31.6+/-4.39mm/h, respectively, at 2 weeks after initiation of IFX. Other inflammatory markers and MMP-3 were also suppressed significantly after 2 weeks of IFX treatment. DAS-28(CRP) and DAS-28(ESR) were also significantly decreased after 2 weeks and suppression of both DAS values remained significant until 54 weeks of IFX treatment. After initiation of IFX, patient-reported general health also showed a significant improvement based on the changes in the six summary component scores on the AIMS2 (physical, affect, symptom, role, social interaction, and patient satisfaction). These scores all improved progressively until 14-18 weeks after initiation of IFX treatment, and then exhibited a temporary but insignificant exacerbation. The six components of the physical score also improved in a time-dependent manner until 14-18 weeks, but the scores for walking and bending, hand and finger function, arm function, self-care, and household tasks showed significant exacerbation at 22-30 weeks. The score for mobility level did not show this change. CONCLUSION: IFX treatment significantly improved both RA disease activity and health status in active RA patients. Time-dependent improvement of ADL until 14-18 weeks after initiation of IFX treatment, as reflected in the six components of the physical score, might have contributed to the temporary exacerbation of health status thereafter in these patients.
Authors:
Akihiko Ban; Masaaki Inaba; Yutaka Furumitsu; Keiji Okamoto; Kazuhiko Yukioka; Hitoshi Goto; Yoshiki Nishizawa
Related Documents :
15088288 - Concomitant medication use in a large, international, multicenter, placebo controlled t...
18821688 - Radiographic findings following two years of infliximab therapy in patients with ankylo...
8758608 - Physiotherapy and occupational therapy for juvenile chronic arthritis: custom and pract...
12858458 - Efficacy and safety of mesalazine (salofalk) in an open study of 20 patients with ankyl...
10051728 - Effect of fluticasone propionate aqueous nasal spray on allergen-induced inflammatory c...
4014268 - "noninvasive" oral treatment of asthma in the emergency room.
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2009-11-05
Journal Detail:
Title:  Biomedicine & pharmacotherapy = Biom?decine & pharmacoth?rapie     Volume:  64     ISSN:  1950-6007     ISO Abbreviation:  Biomed. Pharmacother.     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-02-22     Completed Date:  2010-05-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8213295     Medline TA:  Biomed Pharmacother     Country:  France    
Other Details:
Languages:  eng     Pagination:  107-12     Citation Subset:  IM    
Copyright Information:
2009 Elsevier Masson SAS. All rights reserved.
Affiliation:
Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Asahi-machi, Abeno-ku, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antibodies, Monoclonal / therapeutic use*
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / blood,  drug therapy*
Biological Markers / blood
Blood Sedimentation / drug effects
C-Reactive Protein / metabolism
Female
Health Status*
Humans
Longitudinal Studies
Male
Matrix Metalloproteinase 3 / blood
Middle Aged
Platelet Count
Quality of Life
Rheumatoid Factor / blood
Severity of Illness Index
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Biological Markers; 0/infliximab; 9007-41-4/C-Reactive Protein; 9009-79-4/Rheumatoid Factor; EC 3.4.24.17/Matrix Metalloproteinase 3

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  ADAMTS4 level in patients with stable coronary artery disease and acute coronary syndromes.
Next Document:  Plasma matrix metalloproteinase-9 better predicts outcome than N-terminal protype-B natriuretic pept...